💊
Tecartus
brexucabtagene autoleucel
Lymfom, mantelcells-
✅ Auktoriserad
Avancerad terapi
✅
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.
Vad det används till
Mantle cell lymphoma Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Acute lymphoblastic leukaemia Tecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
⚠️ Patientsäkerhet
No
Officiell EMA-sida
https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus